Recent scientific advances have provided new insights into why leukemia is such a difficult disease to treat and identified molecular processes activated in leukemia stem cells that may facilitate their drug resistance and quiescent cell-cycle status. Monoclonal antibody therapy may be appropriate for malignant cells, and other approaches involve identification and targeting of specific survival pathways for these biologically distinct cells, which are discussed in this Viewpoint article.
